The global plasma fractionation market size was valued at USD 40.27 billion in 2025 and is projected to grow from USD 43.55 billion in 2026 to USD 87.23 billion by 2034, exhibiting a CAGR of 9.1% during the forecast period. North America dominated the plasma fractionation market with a share of 56.22% in 2025, supported by established plasma collection infrastructure, strong demand for plasma-derived therapies, and the presence of leading biopharmaceutical companies.

Plasma Fractionation Market Trends

The global plasma fractionation market is experiencing growth as demand for plasma-derived medicinal products increases across healthcare systems. Plasma fractionation is a specialized process used to separate human plasma into therapeutic proteins, including immunoglobulins, albumin, and coagulation factors. These products are used to manage various immune deficiencies, bleeding disorders, and other medical conditions.

One of the key market trends is the increasing demand for immunoglobulins, which are used to treat several immune-related disorders. Growing awareness of these conditions and improvements in diagnosis are supporting the use of immunoglobulin therapies. Albumin and coagulation factor products also contribute to demand across critical care and specialized treatment settings.

Another important trend is the modernization of plasma fractionation facilities. Manufacturers are investing in advanced processing technologies, production capacity, and quality control systems to improve operational efficiency and product consistency. Improvements in plasma collection, testing, and supply chain management are also important for maintaining a reliable supply of plasma-derived therapies.

Key Growth Drivers of the Plasma Fractionation Market

Rising Demand for Plasma-Derived Therapies: Plasma-derived products play an important role in treating immune deficiencies, bleeding disorders, and certain other medical conditions. Increasing diagnosis rates and the need for long-term treatment are contributing to demand for products such as immunoglobulins, albumin, and clotting factors.

Expansion of Plasma Collection Infrastructure: Plasma fractionation depends on a consistent supply of qualified human plasma. Investments in plasma collection centers, donor recruitment, and collection technologies can help manufacturers secure the raw materials required for production. Expanding collection capacity is particularly important as demand for plasma-derived medicines increases.

Technological Advancements in Fractionation: Manufacturers are adopting advanced separation, purification, and process-monitoring technologies to improve production efficiency and product quality. These investments can help companies optimize manufacturing operations, strengthen quality control, and expand their capacity to supply therapeutic proteins.

Growing Healthcare Expenditure: Increased spending on specialized treatments and improvements in healthcare access are supporting the use of plasma-derived medicines. Demand from hospitals, specialty clinics, and other healthcare providers is expected to remain an important factor shaping market development.

Plasma Fractionation Market Segmentation

The plasma fractionation market can be analyzed by product, application, end user, and geography.

By product, key categories include immunoglobulins, albumin, coagulation factors, and other plasma-derived proteins. Immunoglobulins represent an important product category because of their use in treating several immune-related conditions. Albumin is used in selected clinical settings, including volume replacement and certain critical care applications, while coagulation factors support the management of specific bleeding disorders.

By application, the market serves areas such as immunology, hematology, critical care, and other therapeutic fields. Demand varies according to disease prevalence, treatment guidelines, product availability, and healthcare reimbursement policies.

Hospitals, specialty clinics, and other healthcare institutions represent important end users. Reliable product availability, treatment costs, and established distribution networks influence purchasing decisions across these settings.

North America Dominates the Plasma Fractionation Market

North America accounted for 56.22% of the global plasma fractionation market in 2025, making it the leading regional market. The region benefits from established plasma collection networks, advanced biopharmaceutical manufacturing capabilities, developed healthcare infrastructure, and demand for plasma-derived therapies.

The U.S. plays a significant role in the regional market because of its extensive plasma collection infrastructure and the presence of major plasma product manufacturers. Established treatment pathways and access to specialized healthcare services also support demand for plasma-derived medicines.

Europe represents another important market, supported by established healthcare systems, pharmaceutical manufacturing capabilities, and demand for specialized therapies. Meanwhile, Asia Pacific offers opportunities for market expansion as healthcare infrastructure, diagnostic capabilities, and access to plasma-derived treatments continue to develop. However, regional growth depends on plasma collection capacity, regulatory frameworks, manufacturing investments, and product affordability.

Competitive Landscape of the Plasma Fractionation Market

The global plasma fractionation market features established biopharmaceutical companies and specialized manufacturers competing through product portfolios, production capacity, research and development, plasma collection networks, and geographic expansion. Maintaining high manufacturing standards and a reliable supply of plasma-derived medicines is essential for market participants.

Key companies operating in the market include:

  • CSL (Australia): Through CSL Behring, the company develops and supplies plasma-derived and other specialty therapies.
  • Grifols, S.A. (Spain): A major participant in plasma-derived medicines, with activities spanning plasma collection, fractionation, and therapeutic product development.
  • Takeda Pharmaceutical Company Limited (Japan): Offers plasma-derived therapies for various rare and complex medical conditions.
  • Octapharma AG (Switzerland): Develops and manufactures human protein therapies, including plasma-derived products.
  • Kedrion S.p.A. (Italy): Specializes in plasma-derived products used to treat a range of medical conditions.
  • LFB Group (France): Develops and manufactures biological medicines, including plasma-derived therapeutic products.
  • ADMA Biologics, Inc. (U.S.): Focuses on plasma-derived biologics and therapies for certain infectious and immune-related conditions.
  • GC Biopharma (South Korea): Develops and manufactures plasma-derived products and other biological medicines.
  • Beijing Tiantan Biological Products Co., Ltd. (China): Participates in China's plasma-derived biological products industry.
  • Shanghai RAAS Blood Products Co., Ltd. (China): Focuses on blood products, including plasma-derived therapeutic proteins.

These companies support the market through investments in manufacturing infrastructure, product development, plasma supply, and distribution capabilities. Competitive positioning is influenced by production scale, regulatory compliance, product portfolio breadth, and the ability to maintain consistent supply.

Challenges in the Plasma Fractionation Market

Despite favorable growth prospects, the market faces several operational and commercial challenges. Plasma fractionation requires substantial investment in specialized facilities, advanced purification systems, quality assurance, and regulatory compliance. These requirements can create barriers to entry and make capacity expansion a capital-intensive process.

The availability of suitable human plasma is another important consideration. Collection depends on donor participation, collection center capacity, testing procedures, and strict quality standards. Disruptions in plasma supply can affect manufacturing schedules and product availability.

In addition, plasma-derived medicines require extensive quality controls because they originate from human biological material. Manufacturers must follow stringent procedures for donor screening, pathogen reduction, purification, and product testing. High treatment costs and reimbursement limitations may also restrict access in some markets.

Get Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/plasma-fractionation-market-101614 

Future Outlook

The global plasma fractionation market is projected to grow from USD 40.27 billion in 2025 to USD 87.23 billion by 2034, at a CAGR of 9.1% during the forecast period. Increasing demand for immunoglobulins and other plasma-derived therapies, investments in plasma collection infrastructure, and improvements in manufacturing technologies are expected to support market expansion.

Manufacturers may find opportunities through production capacity expansion, process optimization, research and development, and broader access to plasma-derived treatments. Strengthening plasma collection networks and improving supply chain resilience will remain important priorities.

Overall, the plasma fractionation market is expected to remain an important segment of the biopharmaceutical industry through 2034, driven by the continuing need for specialized therapies and reliable supplies of plasma-derived medicinal products.

Explore Japan’s Market Opportunities - Latest- Plasma Fractionation Market - Insights